

Research Techniques Made Simple: An Introduction to Drug Discovery for Dermatology



Mark Bell¹, Lauren Webster² and Andrew Woodland¹

This article aims to provide an overview of drug discovery with a focus on application within dermatology. The term “drug” can be used to describe a wide variety of agents, including small molecules, cell therapies, and antibodies, which may be dosed intravenously, orally, topically, or by other routes of administration. We summarize the economics and risks involved in drug discovery. Understanding the needs of patients and clinicians through use of a target product profile before initiating drug discovery can reduce time and effort spent developing a poor or unneeded drug. For small molecule drug discovery, a chemical starting point is then required. We present four options for finding a chemical starting point for drug discovery projects: screening libraries of compounds or modifying, reformulating, or repositioning a known drug. Examples of each technique’s use in dermatology are provided. We also describe the subsequent steps involved in discovery of a new drug. To help interested readers, we provide information on how to engage with academic drug discovery centers or industrial partners.

Journal of Investigative Dermatology (2019) 139, 2252–2257; doi:10.1016/j.jid.2019.07.699

CME Activity Dates: 21 October 2019

Expiration Date: 20 October 2020

Estimated Time to Complete: 1 hour

Planning Committee/Speaker Disclosure: All authors, planning committee members, CME committee members and staff involved with this activity as content validation reviewers have no financial relationships with commercial interests to disclose relative to the content of this CME activity.

Commercial Support Acknowledgment: This CME activity is supported by an educational grant from Lilly USA, LLC.

Description: This article, designed for dermatologists, residents, fellows, and related healthcare providers, seeks to reduce the growing divide between dermatology clinical practice and the basic science/current research methodologies on which many diagnostic and therapeutic advances are built.

Objectives: At the conclusion of this activity, learners should be better able to:

- Recognize the newest techniques in biomedical research.
- Describe how these techniques can be utilized and their limitations.
- Describe the potential impact of these techniques.

CME Accreditation and Credit Designation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Beaumont Health and the Society for Investigative Dermatology. Beaumont Health is accredited by the ACCME to provide continuing medical education for physicians. Beaumont Health designates this enduring material for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Physician Participation in Learning Process: The content can be read from the *Journal of Investigative Dermatology* website: <http://www.jidonline.org/current>. Tests for CME credits may only be submitted online at <https://beaumont.cloud-cme.com/RTMS-Nov19> – click ‘CME on Demand’ and locate the article to complete the test. Fax or other copies will not be accepted. To receive credits, learners must review the CME accreditation information; view the entire article, complete the post-test with a minimum performance level of 60%; and complete the online evaluation form in order to claim CME credit. The CME credit code for this activity is: 21310. For questions about CME credit email cme@beaumont.edu.

INTRODUCTION

Drug discovery is a complex, slow, risky and expensive process (Figure 1). It is estimated that it takes, on average, around 10–15 years and \$1.8 billion of investment for each new drug launched (Paul et al., 2010). Only around one in 24 projects successfully deliver a drug, with many failures

occurring toward the end of the process in expensive Phase II and Phase III clinical trials. As a result, drug discovery is dominated by the cost of failure (Figure 1) (Paul et al., 2010).

The pharmaceutical industry delivered many new valuable therapies for dermatology between the 1950s and 1990s (Benedek, 2011). Dermatology then experienced a hiatus,

¹The Drug Discovery Unit, University of Dundee, Dundee, United Kingdom; and ²Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee, United Kingdom

Correspondence: Andrew Woodland, The Drug Discovery Unit, University of Dundee, Nethergate, Dundee, United Kingdom, DD1 4HN.. E-mail: awoodland@dundee.ac.uk

Abbreviations: HDAC, histone deacetylase; JAK, Janus kinase; LO, lead optimization; TPP, target product profile

KEY POINTS

- Drug discovery is expensive, time-consuming, and risky. To discover a drug, it is estimated that on average 24 projects must be started, at a total cost of around \$1.8 billion over 10–15 years.
- Drugs may be small molecules or biological therapies and may be designed for application through a range of routes of administration.
- Before starting a project, the acceptable success criteria are defined in a target product profile.
- The process of discovering a drug can be broken down into a series of stages. Hit identification, hit to lead, and lead optimization describe progress toward inventing a potential drug (discovery); pre-clinical development, Phase I–III clinical trials, and registration are stages of drug evaluation and approval (development).
- There are a number of approaches to the discovery of a small molecule drug, each with their advantages: screening, fast follower, repositioning, and reformulation.

dermatology is attracting record levels of investment, with 28 new approvals in the last 5 years for drugs treating skin disease (Table 1) (CenterWatch, 2019).

TYPES OF DRUGS FOR DERMATOLOGY

Discovering a drug for dermatology is in most ways identical to any other indication. A drug treating a dermatological condition may be an oral, topical, or injectable low-molecular-weight small molecule (usually 200–600 Da). Alternatively, it may be a biological agent such as an antibody, silencing RNA, peptide replacement, or cell therapy. Each type of drug has advantages and disadvantages that must be considered during development. Similarly, the discovery and development of different classes of drug will require the input of specialist experts in drug design, manufacture, and clinical development.

The complexity of drug development means that no one person can discover a drug. Interested parties are therefore encouraged to seek out collaborators or partners who can complement their skill sets.

CENTERS OF EXCELLENCE

In the last 10 years, there has been a large increase in the number of not-for-profit drug discovery facilities. The Academic Drug Discovery Consortium lists 149 centers worldwide (Academic Drug Discovery Consortium, 2018). These centers typically work on a wide range of targets and diseases, although some focus on specific therapeutic areas. The centers can offer a range of capabilities, allowing them to collaboratively run early- to mid-stage projects.

with most therapeutic innovation focusing on the optimization of dosage or delivery vehicles, rather than the discovery of new medicines (Humphries et al., 2016). Today, however,




Figure 1. An overview of the drug discovery process. The numbers for success rate, projects per launch, total cost, and cost of capital were taken from a well-accepted economic model of drug discovery (Paul et al., 2010). Success rate refers to the proportion of projects successfully progressing to the next stage of development. The cumulative success rate allows calculation of the number of projects required at each stage to deliver one new drug launch, on average (No. of projects per launch). Total cost refers to the cumulative cost of all projects required at a given stage of development to deliver one drug launch. The costs include the cost of capital (11%) that accounts for the lost opportunity cost of developing a drug compared with a comparable investment. ID, identification; No., number.

Table 1. FDA Drug Approvals for Dermatology, 2014–2018

2014	2015	2016	2017	2018
Dalvance for acute bacterial skin and skin structure infections	Cosentyx for plaque psoriasis	Ameluz for actinic keratosis	Baxdela for the treatment of acute bacterial skin and skin structure infections	Cimzia for moderate-to-severe plaque psoriasis
Jublia 10% topical gel for onychomycosis of the toenails	Enstilar for psoriasis	Eucrisa ointment for atopic dermatitis	Dupixent for atopic dermatitis	Ilumya for plaque psoriasis
Kerydin for onychomycosis of the toenails	Kybella for submental fat	Taltz for plaque psoriasis	Eskata for seborrheic keratosis	Libtayo for cutaneous squamous cell carcinoma
Orbactiv for acute bacterial skin and skin structure infections	Odomzo for locally advanced basal cell carcinoma		Imbruvica for chronic graft-versus-host disease	Nuzyra for acute bacterial skin and skin structure infections
Otezla for moderate to severe plaque psoriasis			Rhofade for facial erythema associated with rosacea	Qbrexza for primary axillary hyperhidrosis
Sivextro for acute bacterial skin and skin structure infections			Siliq for plaque psoriasis	Seysara for moderate to severe acne vulgaris
Soolantra cream, 1% for inflammatory lesions of rosacea			Tremfya for moderate-to-severe plaque psoriasis	
			Xepi for impetigo	

Abbreviation: FDA, Food and Drug Administration.

The table does not include systemic treatments for metastatic cancers of skin origin or cancers of skin origin with high metastatic potential such as melanoma. Libtayo is approved for locally advanced squamous cell carcinoma as well as metastatic squamous cell carcinoma and is therefore included.

There are, however, few centers that are capable of progressing projects through all stages of a drug discovery process, although these do exist and are increasing in number (Frye et al., 2011; Tralau-Stewart et al., 2014).

Most pharmaceutical companies describe on their websites how they engage with academic or clinical partners. Examples of dermatology-focused companies include Ammirall, LEO Pharma, Galderma-Nestlé Skin Health, Pierre Fabre, GSK-Stiefel, and Maruho Co. Ltd. This list is not exhaustive and there are many other companies (small and large) with an interest in dermatology.

INITIATING A NEW DRUG DISCOVERY PROJECT: DEFINING SUCCESS

Before commencing drug discovery, a project first must consider carefully what patient and healthcare professionals need in a new product. This information is usually gathered in the form of a target product profile (TPP) (Table 2). The TPP is a strategic document that defines the required development outcome. Project teams work back from the

TPP to define the success criteria for each stage of the project (Figure 1). TPPs are rarely published by companies, as they are considered to be commercially sensitive. However, some not-for-profit organizations publish their TPPs, which can serve as useful templates (Drugs for Neglected Diseases Initiative, 2018).

A TPP consists of a series of questions that focus on what is acceptable rather than on desirable traits. For instance, which patient populations are in need of a new therapeutic? Must the drug be taken as a tablet, an injection, or a topical agent? Similarly, what level of clinical benefit is required to replace or supplement the standard of care?

INITIATING A NEW DRUG DISCOVERY PROJECT: FINDING A STARTING POINT

Having defined success criteria with a TPP, the team must then decide where the project will find a chemical or biological starting point. For small molecule drug discovery there are four main options.

Table 2. A List of Common Questions in a TPP

Topics	Objectives
Indications	Disease of study
Populations	Which patient population does the TPP refer to?
Clinical efficacy	What are the weaknesses in the current treatments? What is required to supplant or supplement current treatments?
Safety and tolerability	Are any side effects acceptable? If so, what level of, and what form of, side effects would be tolerated in the patient population?
Stability	How long and in what state can the therapy be stored? Is refrigeration acceptable?
Route of administration	Which routes of administration are acceptable for the indication/patient population?
Dosing frequency	How often and how long is treatment acceptable for the patient population, when considering requirements for cure or maintenance of disease remission?
Cost	What cost would the target patient population (or payer organization) tolerate for a new treatment?

Abbreviation: TPP, target product profile.




Figure 2. An illustration of the fast follower approach. Many JAK inhibitors contain common features (blue), whereas other elements differ (black) with the aim of delivering an improved therapeutic profile for a targeted patient population. Remetinostat contains a common HDAC binding motif (blue) but incorporates metabolically labile esters (red). HDAC, histone deacetylase; JAK, Janus kinase.

Screening

For novel biological targets where there are no known drugs, the project will need to find a small molecule starting point for the project that is called a hit. The most common screening method is high throughput screening. This involves the testing of thousands to millions of diverse chemical compounds either directly against the drug target biochemically (target-based screening) or in a cellular system (phenotypic screening). Active hits should be carefully assessed to ensure that they are true positives.

The hit is then optimized in a phase called hit to lead. An iterative design-make-test approach is employed, where the chemical structure is altered to optimize activity, selectivity, and physical properties. The resulting leads are tested to determine their pharmacokinetic profile and tolerability in animals. If the leads are predicted to be safe and effective, they are then tested in animal models of disease. However, they may be evaluated in cellular or ex vivo models when no suitable animal model exists. If a lead is active in the animal model, and assuming the project has not identified other significant issues, it then progresses into a phase called lead optimization (LO).

In LO, multiparametric optimization is conducted to find the optimal balance of properties, including the drug's physical characteristics and biological activity as well as the pharmacokinetic and safety profile. LO can be a lengthy process that involves large teams of chemists as well as expensive assays and experiments, including employing cellular and animal models of drug exposure,

safety, and efficacy. If successful, LO culminates in the declaration of a preclinical candidate. At this point, the molecular structure of the drug is no longer altered; the drug has been discovered. It will then progress through manufacturing process development and regulatory toxicity testing (preclinical development), to assess safety before initiating human trials (Phase I).

Typically, it is easiest to obtain a patent position in a project that starts from a library screen. However, it is the most time consuming, complex, and expensive approach to drug development. It is important to highlight that historically dermatology has not been the initial focus of drug discovery efforts on novel biological targets. For example, phosphodiesterase 4 (O'Donnell and Zhang, 2004) and Janus kinase (JAK) inhibitors (Hutmacher et al., 2008) were initially evaluated in clinical trials of non-skin diseases before their use in dermatology was explored. Screening approaches to drug discovery therefore have been comparatively rare in dermatology.

Fast follower

The observation of Nobel laureate Sir James Black that "the most fruitful basis for the discovery of a new drug is to start with an old drug" is still true today. This maxim can be applied to repositioning, reformulation, and fast follower approaches to drug discovery, all of which enable researchers to deliver effective therapies to patients in the shortest possible time.

The fast follower approach starts with a known drug that is altered with the aim of delivering an improved therapeutic

MULTIPLE CHOICE QUESTIONS

- According to a published estimate, how much does it cost to discover a drug?
 - \$94 million
 - \$0.9 billion
 - \$1.8 billion
 - \$3.0 billion
- What is a good approach to finding a hit (chemical starting point) for a novel drug target?
 - High throughput screening
 - Repositioning
 - Fast follower
 - Reformulation
- What is the primary deliverable of the lead optimization stage of the drug discovery process?
 - A lead with activity in animal models
 - A preclinical candidate
 - An approved drug
 - A clinical candidate
- What is the main weakness in a repositioning project relative to other approaches?
 - It is more expensive.
 - It is less likely to succeed.
 - Intellectual property protection can be challenging.
 - It requires additional technical expertise.
- How many new projects are required to deliver one new drug?
 - 24
 - 1
 - 10
 - 12

See online version of this article for a detailed explanation of correct answers.

profile. These projects start in the LO phase, skipping the early stages and saving time and effort. Fast followers often aim to deliver improved selectivity and safety profiles. In dermatology, an oral drug may be redesigned and optimized for use as a topical therapy.

The JAK inhibitors are promising therapies under investigation for use in dermatology. Tofacitinib was the first JAK inhibitor to be approved (Cotter et al., 2018). Ruxolitinib and baricitinib, which are being evaluated in clinical trials, may be considered fast followers as they contain many structural features present in tofacitinib (Figure 2) (Cotter et al., 2018). Fast followers often will have altered clinical profiles, as even small changes to a drug's chemical structure can lead to large differences in selectivity or other properties. This is especially evident when the fast follower

is designed for use in a new route of administration, for instance, topical versus oral.

The fast follower approach is well suited to the discovery of topical soft drugs. Soft drugs are stable and active when locally applied to skin but on entering the blood are rapidly metabolized. Remetinostat is a recently discovered soft drug topical histone deacetylase (HDAC) inhibitor that contains a commonly used HDAC binding motif but incorporates ester soft drug groups that are rapidly metabolized (Figure 2). In a phase II trial for the treatment of mycosis fungoides, 40% of patients treated twice daily with 1% remetinostat gel achieved a confirmed response but lacked the side effects associated with systemic HDAC inhibitors (Duvic et al., 2018).

A key benefit of a fast follower approach over repositioning or reformulation is that it enables composition of matter patents to be filed covering the intellectual property associated with the new drug. This protects the interests of the drug discovery companies or investors who must pay for expensive clinical trials.

Repositioning

The quickest approach to drug discovery is the repurposing or repositioning of existing drugs (Barratt and Frail, 2012). Although only approximately 10% of new chemical entity applications obtain market approval, it is estimated that nearly 30% of repurposed drugs do so, providing a significant incentive for finding ways to repurpose existing drugs (Kaiser, 2011).

Discovering a new use for an existing drug has some clear advantages. In general, the safety, efficacy, and toxicity of the existing drug has been studied extensively. Repurposed drugs do however require some exposure to the drug discovery process to check that the drug is effective in disease relevant models of the proposed indication.

As the chemical structure of the drug is not novel, composition of matter patents are not an option; however, other approaches to gaining a commercially viable product may be possible, such as filing a use patent or seeking regulatory protection (Smith, 2011).

A fascinating example for dermatology is the repurposing of thalidomide, a drug previously used as a sedative that had the adverse effect of causing thousands of birth defects (McBride, 1961). In 1998, thalidomide was approved as a new treatment for erythema nodosum leprosum, a painful skin condition arising in patients with leprosy (Figure 2) (Teo et al., 2002). By avoiding treatment of pregnant mothers, the primary side effect (birth defects) is avoided. A recent study of the topical pharmacokinetics of tofacitinib (Purohit et al., 2019) illustrates a general observation that topical application of a drug to a body surface area of <30% rarely leads to a systemic drug concentration sufficient to lead to side effects. Repositioning can therefore be a particularly effective strategy in dermatology.

Reformulation

Reformulation is a subcategory of repositioning that is common in dermatology. It is often used when it is desirable to reposition an existing drug for use in a dermatological condition, but the existing drug has been

formulated for oral use (Abadir et al., 2018). It is also used to combine two effective agents into one formulation to simplify treatment regimens or to provide an optimal dosage for improved efficacy. The reformulation of oral drugs for topical use still requires development of a safe and patient-friendly formulation and testing in animal models to assess the safety and efficacy of the new formulation before human clinical trials.

A recent example of reformulation is valsartan (Abadir et al., 2018). Valsartan is an approved therapy for the management of blood pressure (Figure 2). In preclinical studies, 1% valsartan gel accelerated wound closure in mice and porcine models, and the approach may provide a valuable new therapy for the treatment of chronic wounds in patients with diabetes (Abadir et al., 2018).

SUMMARY

In the authors' experience, the most effective drug discovery projects involve a wide range of stakeholders. We hope that in this article we have provided an outline of why drug discovery matters, what's involved, and how you, the reader, can contribute to the development of meaningful new therapies for patients.

ORCIDiS

Mark Bell: <https://orcid.org/0000-0002-8166-0208>

Lauren Webster: <https://orcid.org/0000-0001-5192-7584>

Andrew Woodland: <https://orcid.org/0000-0003-2571-2699>

CONFLICT OF INTEREST

The authors state no conflict of interest.

ACKNOWLEDGMENTS

The authors recognize Kevin Read, PhD for his expertise, contribution, and oversight during the preparation of this manuscript. This article was written by staff supported under funding from Scottish Enterprise, United Kingdom (PS730566-In4Derm) and a Wellcome Trust Centre Award, United Kingdom (203134/Z/16/Z).

AUTHOR CONTRIBUTIONS

Conceptualization: AW, MB; Supervision: AW; Writing - Original Draft Preparation: AW, MB, LW; Writing - Review and Editing: AW, MB, LW.

SUPPLEMENTARY MATERIAL

Supplementary material is linked to this paper. Teaching slides are available as supplementary material.

REFERENCES

- Abadir P, Hosseini S, Faghieh M, Ansari A, Lay F, Smith B, et al. Topical reformulation of valsartan for treatment of chronic diabetic wounds. *J Invest Dermatol* 2018;138:434–43.
- Academic Drug Discovery Consortium (ADDC), <http://addconsortium.org/index.php>; (accessed 9 April 2018).
- Barratt MJ, Frail DE, editors. Drug repositioning: bringing new life to shelved assets and existing drugs. NJ: Wiley; 2012.
- Benedek TG. History of the development of corticosteroid therapy. *Clin Exp Rheumatol* 2011;29(5 Suppl. 68):S5–12.
- CenterWatch, <https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/3/dermatology>; (accessed 7 January 2019).
- Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. *J Am Acad Dermatol* 2018;78(3 Suppl. 1):S53–62.
- Drugs for neglected diseases initiative (DNDi), Target Product Profiles (TPP), <https://www.dndi.org/diseases-projects/target-product-profiles/>; (accessed 16 September 2018).
- Duvic M, Guitart J, Huen A, Porcu P, LeBoeuf NR, Skolnik J, et al. Anti-pruritic properties of remetinostat (SHAPE), a topical histone deacetylase inhibitor (HDACi); data from a randomized phase 2 study in patients with stage IA-IIA mycosis fungoides. *J Invest Dermatol* 2018;138:S103.
- Frye S, Crosby M, Edwards T, Juliano R. US academic drug discovery. *Nat Rev Drug Discov* 2011;10:409–10.
- Humphries B, Kaplan R, Alves M. The role of entrepreneurial leadership and innovation in the future of therapeutic dermatology. *J Invest Dermatol* 2016;136:2330–3.
- Hutmacher MM, Krishnaswami S, Kowalski KG. Exposure–response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. *J Pharmacokinetic Pharmacodyn* 2008;35:139–57.
- Kaiser J. Biomedicine. NIH's secondhand shop for tried-and-tested drugs. *Science* 2011;332:1492.
- McBride WG. Thalidomide and congenital malformations. *Lancet* 1961;2:90927–8.
- O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). *Trends Pharmacol Sci* 2004;25:158–63.
- Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nat Rev Drug Discov* 2010;9:203–14.
- Purohit VS, Ports WC, Wang C, Riley S. Systemic tofacitinib concentrations in adult patients with atopic dermatitis treated with 2% tofacitinib ointment and application to pediatric study planning. *J Clin Pharmacol* 2019;59:811–20.
- Smith RB. Repositioned drugs: integrating intellectual property and regulatory strategies. *Drug Discov Today Ther Strateg* 2011;8:131–7.
- Teo S, Resztk KE, Scheffler MA, Kook KA, Zeldis JB, Stirling DI, et al. Thalidomide in the treatment of leprosy. *Microbes Infect* 2002;4:1193–202.
- Tralau-Stewart C, Low CM, Marlin N. UK academic drug discovery. *Nat Rev Drug Discov* 2014;13:15–6.

RESEARCH TECHNIQUES MADE SIMPLE

DETAILED ANSWERS

1. **According to a published estimate, how much does it cost to discover a drug?**

Answer: C. \$1.8 billion.

The cost of drug discovery is estimated as being around \$1.8 billion. This cost includes the cost of failure and accounts for the cost of investing in projects that may take more than a decade to deliver a new medicine.

2. **What is a good approach to finding a hit (chemical starting point) for a novel drug target?**

Answer: A. High throughput screening.

Unless there are published examples of prototype or approved drugs, then the only option for a new project is to screen (test) a library of potential drugs to find the starting point (hit) for the project.

3. **What is the primary deliverable of the lead optimization stage of the drug discovery process?**

Answer: B. A preclinical candidate.

The lead optimization phase leads to the discovery of a pre-clinical candidate (the prospective drug). The prospective drug is then named a clinical candidate once it has passed preclinical development.

4. **What is the main weakness in a repositioning project relative to other approaches?**

Answer: C. Intellectual property protection can be challenging.

Repositioning is an attractive approach but it can be challenging to protect the intellectual property, as the drug itself is already known and the use may have been suggested in the literature, thus preventing patent protection.

5. **How many new projects are required to deliver one new drug?**

Answer: A. 24.

Most drug discovery projects fail and it requires around 24 new projects to deliver one drug approval on average.